Analysts on Wall Street have probably spent more time thinking about the price of stocks than you have, because it's their full-time job. That doesn't mean they're always correct, but it does suggest that there's a lot to learn from understanding their estimates and thinking about how they're made.On that note, per their consensus estimate, analysts are anticipating that two biotech stocks in particular could more than double their current value within the next 12 months. There's no guarantee it'll happen f ...

Presentation and Q&A session scheduled for post-market on Thursday, February 29, 2024 BOSTON, Feb. 22, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2023, on Thursday, February 29, 2024, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available ...

合作伙伴关系 - Ginkgo Bioworks和SaponiQx获得MCDC合同，通过生成分子设计发现和制造下一代疫苗佐剂[2] - SaponiQx的STIMULON™ QS-21是带状疱疹、疟疾和呼吸道合胞病毒等领先疫苗的关键佐剂成分[3] - 合作伙伴旨在通过实验室和动物研究展示这些新型佐剂对抗生物威胁剂的能力，以及通过利用Ginkgo的领先细胞编程平台提供更低成本、可持续和可扩展的制造过程[5]

Ginkgo的生物技术应用 - 国会议员参观了Ginkgo在波士顿海港总部，讨论了加强美国在生物技术人工智能应用方面的竞争能力，以及解锁制药、农业等行业的创新[1] - Ginkgo的Foundry生成了重要的数据资产和工具，使公司能够更可靠地开发生物技术产品[1] - Ginkgo的设施在波士顿占据了超过500,000平方英尺的现有和计划容量，类似于芯片工厂和云数据中心在推动数字经济和人工智能进步方面发挥的作用，这些设施可以成为生物经济的关键推动者[1] Ginkgo的研发能力增强 - Ginkgo的Biofab1设施预计将在完全运营时显著增加Ginkgo的研发服务能力[1] - Biofab1预计将于明年初开始运营，旨在显著增加Ginkgo生成生物数据的能力[5] Ginkgo的生物数据和人工智能 - Ginkgo的Foundry为公司提供了所需的灵活性和规模，以更容易地开发和商业化基于生物的产品[3] - Foundry和Biofab1在新的生成式人工智能能力下具有额外的国家安全意义，生物数据变得尤为重要[4] - Ginkgo的领导层认为，在生物经济中取得领导地位将需要在这些人工智能模型的发展方面处于领先地位[8]

KETCHUM, Idaho, Feb. 1, 2024 /PRNewswire/ -- Light Bio, an innovative synthetic biology startup, today announced that it is beginning to sell its groundbreaking bioluminescent petunias in the United States. With support from notable biotech leaders such as NFX and Ginkgo Bioworks (NYSE: DNA), Light Bio is reimagining the horticultural industry by introducing a new category of plants that emit an ethereal glow to enrich homes, gardens, and public spaces. Bioluminescent plants are now even brighter: Light ...

合成生物学公司Ginkgo Bioworks - Ginkgo Bioworks是全球领先的合成生物学公司，专注于生产具有非自然有价值特性的微生物品种[4] - 公司的发酵业务在2023年第三季度新增了21个新的细胞项目，但收入仅达到3700万美元，远远不足以维持生计[5] COVID-19大流行下的Ginkgo Bioworks - Ginkgo Bioworks的诊断业务在COVID-19大流行初期成为传染病监测的主要提供商，但这并不使股票非常具有吸引力[9]

Cathie Wood投资动向 - Cathie Wood本周增持了Meta Platforms、Recursion Pharmaceuticals和Ginkgo Bioworks[2] Meta Platforms财务表现 - Meta Platforms去年股价涨幅接近200%，营收增长21%至342亿美元[3][4][5] Citi分析师观点 - Citi分析师将Meta Platforms股价目标从425美元上调至440美元，认为其是2024年互联网股中表现最佳的股票[6][7][8]

The companies plan to join forces to set up pathogen monitoring programs utilizing Illumina technology across Concentric's global network  BOSTON and SAN DIEGO, Jan. 15, 2024 /PRNewswire/ -- Concentric by Ginkgo, the biosecurity and public health unit of Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it has entered into a Co-Marketing Agreement with Illumina, Inc. (Nasdaq: ILMN), a global leader in DNA sequencing and array-based ...

Expects to meet 2023 new program and revenue guidance ranges Ended the year with nearly $950 million in cash and cash equivalents, a strong balance sheet providing multi-year runway as Ginkgo sees operational efficiencies in the business Strong growth among blue chip pharma and biotech ("biopharma") customers including Pfizer, Novo Nordisk, Merck and Boehringer Ingelheim Management to highlight updates today at the 42nd Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PT (12:45 p.m. ET) BOSTON, Jan. 10 ...

Ginkgo Bioworks与Biogen合作 - Ginkgo Bioworks与Biogen成功完成基因治疗项目，旨在重新定义重组腺相关病毒（AAV）基因疗法制造的行业标准[1] - Ginkgo Bioworks是领先的细胞编程横向平台，提供灵活的端到端服务，解决各种市场的挑战，包括食品和农业、制药、工业和特种化学品等[2] - Ginkgo Bioworks的前瞻性声明指出，合作伙伴关系和细胞编程平台的能力和潜在成功受到当前预期和假设的影响，存在风险和不确定性[3]